Trial results comparing Restriction Spectrum Imaging (RSI) to conventional breast MRI for breast cancer screening were posted on ClinicalTrials.gov on 2026-04-17. The study found that conventional breast MRI identified 34 participants with cancer, while Restriction Spectrum Imaging (RSI) identified 0 participants with cancer.
Background
Breast cancer remains a significant global health concern, and early detection through screening is crucial for improving patient outcomes. Magnetic Resonance Imaging (MRI) is a well-established screening tool, particularly for individuals at high risk, offering detailed imaging that can detect cancers not visible on mammography. However, conventional breast MRI can be time-consuming and costly. Investigating alternative or abbreviated imaging techniques, such as Restriction Spectrum Imaging (RSI), is important for potentially enhancing screening accessibility and efficiency while maintaining diagnostic accuracy.
Trial design
This completed trial (NCT03495115) enrolled 460 participants to compare Restriction Spectrum Imaging (RSI) with conventional and abbreviated breast MRI for breast cancer screening. The study focused on participants with Breast Cancer. The primary objective, as indicated by the key outcome measurements, was to assess the diagnostic accuracy of RSI in comparison to conventional breast MRI for detecting breast cancer in a screening population. The trial compared the performance of Restriction Spectrum Imaging (RSI) against a conventional Dynamic Contrast-Enhanced MRI (DCE MRI) approach.
Key results
The diagnostic accuracy for the detection of breast cancer in the screening population yielded the following results:
- For the DCE MRI group, 34 participants were identified with cancer.
- For the Restriction Spectrum Imaging (RSI) group, 0 participants were identified with cancer.
A key analysis was performed using ANOVA, resulting in a p-value of 0.05.
What this means
The results from this completed trial indicate that Restriction Spectrum Imaging (RSI), as applied in this study, did not identify any participants with breast cancer, in contrast to conventional DCE MRI which identified 34 participants. This suggests that RSI, in this specific screening context, did not demonstrate comparable diagnostic accuracy to conventional breast MRI for cancer detection. These findings are important for guiding further research and clinical application of advanced imaging techniques in breast cancer screening.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03495115, titled "Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening," were posted on 2026-04-17 on clinicaltrials.gov.